Sarcoma News & Features
The search for evidence to support the growing use of proton therapy for more cancers continues to uncover valuable findings. New data from clinical trials demonstrate the potential advantages of proton therapy over conventional radiation for pancreatic cancer, late-stage non-small cell lung cancer, chordoma, and chondrosarcoma.
Among children with intermediate-risk rhabdomyosarcoma that is negative for a fusion gene, those who had a high score of the specific gene signature MG5 had poorer survival outcomes compared with those who had a low score of MG5.
The FDA has approved trabectedin (Yondelis) for treatment of unresectable or metastatic soft tissue sarcoma.
A large prospective postcommercialization study in patients with advanced STS in Europe confirmed the long-term anticancer activity of trabectedin (Yondelis) in different subtypes of sarcoma.
Single-agent aldoxorubicinshowed superior efficacy over doxorubicin and manageable adverse effects in advanced soft-tissue sarcoma.
A diagnosis of soft-tissue sarcoma can leave many patients unsure of what to do next. This fact sheet provides more information about this type of cancer and lists sources of support.
- Existing Drug May Limit Recurrence and Metastasis of Glioblastoma Multiforme
- New Blood Test Improves Screening for Prostate Cancer
- Blood Sample Offers a New Way of Detecting Cancer
- Nanoliposomal Irinotecan Extends Survival in Metastatic Pancreatic Cancer
- International Study Charts Genetic Trajectory for Melanoma
- Breastfeeding Associated With A Reduced Risk of Aggressive Breast Cancer
- Hospitals Should Enact Bereavement Programs, Researchers Urge
- Physical Activity Communications Should be Part of Oncology Care Clinic Visits With Patients
- Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy
- Communication Practices of Many US Physicians May Be Discouraging HPV Vaccination
- Late-onset Remission Seen in Patients With Lymphoma Treated with Immunomodulatory Drugs
- Impact of Early Palliative Care Varies Depending on Patient Age, Gender
- Weight Gain May Follow Head and Neck Cancer Operations
- Patients With Prostate Cancer Receiving Active Surveillance May Not Be Properly Monitored
- FDA Approves Elotuzumab for Multiple Myeloma Combination Therapy
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|